Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other ...